Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Pediatric/Young Adult R/R ALL/LL (DELPHINUS)
NCT03384654Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of daratumumab in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by Janssen Pharmaceutical. Started May 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT03384654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384654.